Home Cart Sign in  
Chemical Structure| 329-89-5 Chemical Structure| 329-89-5

Structure of 6-Aminonicotinamide
CAS No.: 329-89-5

Chemical Structure| 329-89-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

6-Aminonicotinamide is a precursor for antidiabetic drugs that inhibits NAD+-dependent enzymes. 6-Aminonicotinamide has inhibitory effects on NAD+-dependent acetyltransferases and is mainly used in research on diabetes and related metabolic diseases.

Synonyms: 6-AN; SR 4388; NSC 21206

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 6-Aminonicotinamide

CAS No. :329-89-5
Formula : C6H7N3O
M.W : 137.14
SMILES Code : O=C(N)C1=CN=C(N)C=C1
Synonyms :
6-AN; SR 4388; NSC 21206
MDL No. :MFCD00006327
InChI Key :ZLWYEPMDOUQDBW-UHFFFAOYSA-N
Pubchem ID :9500

Safety of 6-Aminonicotinamide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
ES2 cells 10 µM To study the effect of 6-Aminonicotinamide on CMA activity, results showed that 6-AN, as a CMA activator, could decrease the protein levels of EIF4A1, EIF4H, and DDX3X. Autophagy. 2019 Sep;15(9):1558-1571.
SUM159 cells 10 µM To study the effect of 6-Aminonicotinamide on CMA activity, results showed that 6-AN, as a CMA activator, could decrease the protein levels of EIF4A1, EIF4H, and DDX3X. Autophagy. 2019 Sep;15(9):1558-1571.
C33A cells 26.78 μM 6 days Inhibit HPV16 E6-induced cell proliferation Redox Biol. 2024 May;71:103108.
PHKs cells 81.06 μM 6 days Inhibit HPV16 E6-induced cell proliferation Redox Biol. 2024 May;71:103108.
Mouse microglia-enriched cultures 10 μM 2 days Inhibition of G6PD activity, reducing LPS-induced oxidative stress J Neuroinflammation. 2019 Dec 5;16(1):255.
Rat mesencephalic neuron-glia co-cultures 10 μM 7 days Inhibition of G6PD activity, attenuating LPS-induced dopaminergic neurodegeneration J Neuroinflammation. 2019 Dec 5;16(1):255.
Tsc2-deficient cells 10 μM 1 hour Inhibited G6PD activity, reduced NADPH levels, increased ROS production, and decreased cell survival Cell Death Dis. 2014 May 15;5(5):e1231.
Neutrophils 10^-6 M 15 min Inhibition of HMPS activity and random migration J Clin Invest. 1974 Mar;53(3):813-8.
Human neutrophils 10^-8 M 20 minutes no significant effect on HMPS activity or glycolysis, chemotactic responsiveness remained near normal J Clin Invest. 1974 Feb;53(2):591-9.
Human neutrophils 10^-5 M 20 minutes mildly inhibited HMPS activity with no effect on glycolysis, resulting in a smaller reduction in chemotactic responsiveness J Clin Invest. 1974 Feb;53(2):591-9.
Human neutrophils 10^-1 M 20 minutes inhibited HMPS activity without affecting glycolytic enhancement, leading to a 23-45% reduction in chemotactic responsiveness J Clin Invest. 1974 Feb;53(2):591-9.
Hepatocytes 1 mM 10 minutes Inhibition of G6PD activity, reduction in superoxide anion production Free Radic Biol Med. 2009 Aug 1;47(3):219-28.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Xenograft model Subcutaneous injection 4 mg/kg/3d Every 3 days for 3 weeks Inhibit HPV16 E6-induced tumor growth Redox Biol. 2024 May;71:103108.
C57BL/6J mice LPS-induced Parkinson's disease model Intranigral injection 20 nmol Single injection, observed for 6 weeks Inhibition of G6PD activity, attenuating LPS-induced oxidative stress, microglial activation, dopaminergic neurodegeneration, and locomotor impairment J Neuroinflammation. 2019 Dec 5;16(1):255.
Mouse AXB and BXA recombinant inbred (RI) mouse strains Intraperitoneal injection 9 mg/kg Single dose on day 13 of pregnancy To study the genetic susceptibility to 6-AN-induced cleft palate, identifying several chromosomal regions potentially associated with susceptibility. Proc Natl Acad Sci U S A. 1997 May 13;94(10):5231-6
Zucker fa/fa rats Type 2 diabetes model Liver perfusion 5 mM 10 minutes Inhibition of G6PD activity, reduction in superoxide anion production Free Radic Biol Med. 2009 Aug 1;47(3):219-28.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

7.29mL

1.46mL

0.73mL

36.46mL

7.29mL

3.65mL

72.92mL

14.58mL

7.29mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories